natgillin/translations-raw huggingface dataset:
The veterinary product must be administered intraarticularly, only by a veterinary surgeon, taking special precautions to ensure the sterility of the injection process. 
Način uporabe Zdravilo za uporabo v veterinarski medicini mora intraartikularno dati izključno veterinar in pri tem upoštevati previdnostne ukrepe za zagotavljanje sterilnosti postopka injiciranja.
NAME OF THE VETERINARY MEDICINAL PRODUCT HorStem suspension for injection for horses 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI HorStem suspenzija za injiciranje za konje
4.2 Indications for use, specifying the target species Reduction of lameness associated with mild to moderate degenerative joint disease (osteoarthritis) in horses. 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Zmanjšanje šepavosti, povezane z blago do zmerno degenerativno boleznijo sklepov (osteoartritisom) pri konjih.
TARGET SPECIES Horses 
CILJNE ŽIVALSKE VRSTE Konji
In case of severe inflammation, administration of symptomatic treatment with NonSteroidal Anti-Inflammatory Drugs (NSAIDs) could be necessary. 
V primeru hudega vnetja je morda potrebno simptomatsko zdravljenje z nesteroidnimi protivnetnimi zdravili (NSAID).
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports) 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 živalih od 100 zdravljenih živali) - občasni (pri več kot 1, toda manj kot 10 živalih od 1.000 zdravljenih živali)
Complete remission was observed within 3 days, without any symptomatic treatment. 
V naslednjih treh dneh so brez simptomatskega zdravljenja opazili popolno remisijo.
The active substance, mesenchymal stem cells, is considered as not falling within the scope of the MRL regulation, as it is covered by the entry for stem cells in the list of substances considered as not falling within the scope of Regulation (EC) No 470/2009. 
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) Učinkovina, mezenhimske matične celice, ne spada v področje uporabe uredbe o vrednostih MRL, saj je vključena v rubriko za matične celice na seznamu snovi, ki ne spadajo v področje uporabe Uredbe (ES)
Cloudy colourless suspension. 
Motna brezbarvna suspenzija.
ADVICE ON CORRECT ADMINISTRATION Do not apply simultaneously with other intraarticular veterinary medicinal products. 
NASVET O PRAVILNI UPORABI ZDRAVILA Ne dajajte hkrati z drugimi intraartikularnimi zdravili za uporabo v veterinarski medicini.
PACKAGE LEAFLET: HorStem suspension for injection for horses 
NAVODILO ZA UPORABO: HorStem suspenzija za injiciranje za konje
A single intraarticular injection of 1 ml (15x106 equine umbilical cord mesenchymal stem cells) into the affected joint. 
Ena intraartikularna injekcija z 1 ml (15 x 106 konjskih popkovničnih mezenhimskih matičnih celic) v prizadeti sklep.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Route of administration: 
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA
ROUTE(S) OF ADMINISTRATION Intraarticular use 
POT(I) UPORABE ZDRAVILA Intraartikularna uporaba
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PROIZVAJALEC BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ
FOR ANIMAL TREATMENT ONLY For animal treatment only. 
SAMO ZA ŽIVALI Samo za živali.
Equine umbilical cord mesenchymal stem cells (EUC-MSCs) 
Učinkovina: Konjske popkovnične mezenhimske matične celice (EUC-MSC)
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product. 
Uredbe Komisije (EU) št. 37/2010 določa, da MRL ni potreben, ali pa ne spadajo v področje uporabe
4.7 Use during pregnancy, lactation or lay 
4.7 Uporaba v obdobju brejosti, laktacije ali nesnosti Varnost zdravila v obdobju brejosti in laktacije ni bila ugotovljena.
To be supplied only on veterinary prescription. 
Zdravilo sme dati samo veterinar.
An increase in mild lameness was observed 24 hours after HorStem administration. 
24 ur po dajanju zdravila HorStem so opazili povečanje blage šepavosti.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml dose contains: 
Vsak 1-ml odmerek vsebuje:
Do not administer simultaneously with any other intraarticular veterinary medicinal product. 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Ne dajajte hkrati z nobenim drugim intraartikularnim zdravilom za uporabo v veterinarski medicini.
Acute synovitis with an acute onset of severe lameness, joint effusion and pain on palpation was reported 24 hours after administration of the veterinary medicinal product. 
Zelo pogosti Poročali so, da se je 24 ur po dajanju zdravila za uporabo v veterinarski medicini pojavil akutni sinovitis z akutnim nastopom hude šepavosti, efuzijo sklepa in bolečino ob palpaciji.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE OUTER CARTON 
PODATKI NA ZUNANJI OVOJNINI ZUNANJA ŠKATLA
4.8 Interaction with other medicinal products and other forms of interaction 
4.8 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Ne dajajte hkrati z nobenim drugim intraartikularnim zdravilom za uporabo v veterinarski medicini.
Active Substance: 15x106 Equine umbilical cord mesenchymal stem cells 
Učinkovina: 15 x 106 konjskih popkovničnih mezenhimskih matičnih celic
QUANTITY OF THE ACTIVE SUBSTANCE(S) 15x106 /ml Equine umbilical cord mesenchymal stem cells 
KOLIČINA UČINKOVIN(E) 15 x 106/ml konjskih popkovničnih mezenhimskih matičnih celic
In order to collect further field data, related to both safety and efficacy, from batches that have been released by use of the updated potency assay, the marketing authorisation holder shall conduct and submit the results of a surveillance study. 
Imetnik dovoljenja za promet z zdravilom mora izvesti nadzorno študijo in predložiti njene rezultate, da bi zbral več terenskih podatkov, povezanih z varnostjo in učinkovitostjo, iz serij, sproščenih z uporabo posodobljenega testa jakosti.
15x106 /ml Equine umbilical cord mesenchymal stem cells 
15 x 106/ml konjskih popkovničnih mezenhimskih matičnih celic
Method of administration: 
Pot uporabe zdravila::
Moderate joint effusion with no associated lameness has been observed 24 hours after HorStem administration. 
24 ur po dajanju zdravila HorStem so opazili zmerno efuzijo sklepa brez povezane šepavosti.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: Da bi se izognili samoinjiciranju, je potrebna previdnost.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
- zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
Special precautions to be taken by the person administering the veterinary medicinal product to animals 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Da bi se izognili samoinjiciranju, je potrebna previdnost.
Lactobionic acid 
Pomožna snov: adenozin dekstran-40 laktobionska kislina
L- Glutathione 
OVOJNINAH VIALA
• It looks damaged. 
• Videti je poškodovan.
Your doctor will decide if and when you may restart the treatment: 
Zdravnik se bo odločil, če in kdaj lahko znova začnete z zdravljenjem:
1 GET READY 
1 PRIPRAVITE SE
Date of first authorisation: 25 April 2016 
Datum prve odobritve: 25. april 2016
However, the physician should ensure appropriate follow-up of patients. 
Kljub temu mora zdravnik zagotoviti ustrezno spremljanje bolnikov.
- if you have Crohn's disease. 
- če imate Crohnovo bolezen.
Check the label. 
Preglejte oznako.
Number of patients (%) 
Število bolnikov (%)
(minimal) 
(minimalno)
- pain in the back of the throat. 
- bolečina v zadnjem delu grla,
- if you have an infection which your doctor thinks is important (for example, active tuberculosis). 
- če imate okužbo, ki jo je vaš zdravnik ocenil za pomembno (na primer aktivno tuberkulozo).
1f Prepare your skin. 
1f Pripravite kožo.
The effects of this medicine in pregnant women are not known. 
Vpliv tega zdravila na nosečnice ni znan.
- if you have ulcerative colitis. 
- če imate ulcerozni kolitis.
You are now ready to inject. 
Zdaj ste pripravljeni na injiciranje.
Clinical response at 12 weeks 
Klinični odziv po 12 tednih
Week 24 data are presented in Table 9. 
Podatki iz 24. tedna so predstavljeni v Preglednici 9.
Important points to know 
Pomembne točke, s katerimi morate biti seznanjeni
If you have psoriatic arthritis you will first be given other medicines. 
Če imate psoriatični artritis, boste najprej prejeli druga zdravila.
DO NOT inject in the exact same spot every time. 
NE injicirajte zdravila vsakokrat na isto mesto.
Your doctor or nurse will regularly monitor your condition to check that the treatment is having the desired effect. 
Vaš zdravnik ali medicinska sestra bosta redno spremljala vaše stanje, da se bosta prepričala, ali ima vaše zdravljenje želeni učinek.
A. Some patients may hear a soft click right before the second loud click. 
O: Nekateri bolniki lahko slišijo tišji klik tik pred drugim glasnim klikom.
Quality of Life/Patient-Reported Outcomes 
Kakovost življenja/izidi po navedbah bolnikov
Bottom/ End Needle minutes 
Dno/ Konec igle minut
This will not harm you or affect your dose. 
Ne bo vam škodila, niti ne bo vplivala na vaš odmerek.
Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks. 
Pri nekaterih bolnikih z začetnim delnim odzivom se stanje ob nadaljevanju zdravljenja prek 20 tednov lahko izboljša.
A. This is not necessary, but it may help you keep the pre-filled pen steady and firm against your skin. 
O: To ni potrebno, morda pa vam bo pomagalo, da boste napolnjeni injekcijski peresnik držali bolj mirno in trdno na koži.
Week 52 Ixekizumab* Ustekinumab** Ixekizumab* Ustekinumab** Ixekizumab* Ustekinumab** 
52. teden iksekizumab* ustekinumab** iksekizumab* ustekinumab** iksekizumab ustekinumab**
Such levels of neutropenia may persist, fluctuate or be transient. 
Te ravni nevtropenije se lahko ohranijo, nihajo ali pa so prehodne.
Insert the needle at a 45-degree angle. 
Vstavite iglo v kožo pod kotom 45 stopinj.
A. If the plunger is stuck or damaged: 
O: Če se je bat zataknil ali je poškodovan:
Your doctor will decide how much Taltz you need and for how long. 
Zdravnik bo presodil, koliko zdravila Taltz potrebujete in kako dolgo.
A. When your injection is complete: 
O: Ko je vaše injiciranje končano:
A. After you press the green injection button, you will hear 2 loud clicks. 
O: Ko pritisnete zeleni gumb za injiciranje, boste slišali dva glasna klika.
It may harm them, 
Občasni urtikarija,
There will be a loud click. 
Slišali boste glasen klik.
Taltz must not be given to patients with active tuberculosis (TB). 
Zdravila Taltz se ne sme dajati bolnikom z aktivno tuberkulozo (TB).
No data are available on the response to live vaccines; there are insufficient data on response to inactive vaccines (see section 5.1). 
Podatkov o odzivu na živa cepiva ni na voljo; podatki o odzivu na inaktivirana cepiva niso zadostni (glejte poglavje 5.1).
Wait 30 minutes to let the syringe warm to room temperature before you use it. 
Počakajte 30 minut, da se brizga ogreje na sobno temperaturo, preden jo uporabite.
- if you are allergic to ixekizumab or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na iksekizumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
• DO NOT continue to use the syringe. 
• NE nadaljujte z uporabo brizge.
Make sure the name Taltz appears on the label. 
Prepričajte se, da je na oznaki ime Taltz.
Keep the base on your skin, and then turn the lock ring to the unlock position. 
Držite podnožje na koži, nato pa obrnite zaklepni obroč v odklenjeni položaj.
Use a reminder method such as notes in a calendar or diary to help you remember your next dose so that you avoid missing or repeating doses. 
Uporabljajte opomnike, npr. zapise na koledar ali v dnevnik, da se boste spomnili na vaš naslednji odmerek in se izognili izpuščanju ali podvajanju odmerkov.
No apparent association between the presence of neutralising antibodies and impact on drug concentration or efficacy was observed. 
Očitne povezave med prisotnostjo nevtralizirajočih protiteles in vplivom na koncentracijo ali učinkovitost zdravila niso opazili.
Make sure the lock ring is in the lock position. 
Prepričajte se, da je zaklepni obroč v zaklenjenem položaju.
Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment. 
Ženske v rodni dobi morajo med zdravljenjem in vsaj 10 tednov po njem uporabljati učinkovito kontracepcijsko metodo.
You will also see the grey plunger at the top of the clear base. 
Prav tako boste zdaj videli sivi bat na vrhu prozornega podnožja.
Patients in all treatment groups with an inadequate response at week 16 received rescue therapy (modification to background therapy). 
Bolniki v vseh skupinah zdravljenja, ki so imeli v 16. tednu nezadosten odziv, so prejeli rešilno zdravljenje (prilagoditev osnovnemu zdravljenju).
For both studies, the primary endpoint was American College of Rheumatology (ACR) 20 response at Week 24. 
Za obe študiji je bil primarni opazovani dogodek odziv ACR 20 (American College of Rheumatology) v 24. tednu.
• Your doctor, pharmacist or nurse may help you decide where on your body to inject your dose. 
• Zdravnik, farmacevt ali medicinska sestra vam lahko pomagajo pri odločitvi, na katero mesto na vašem telesu si boste injicirali svoj odmerek.
Taltz is for long-term treatment. 
Zdravilo Taltz je namenjeno za dolgoročno zdravljenje.
If you stop treatment, symptoms of psoriasis or psoriatic arthritis may come back. 
Če prenehate z zdravljenjem, se lahko simptomi psoriaze ali psoriatičnega artritisa znova pojavijo.
DO NOT use any heat sources to warm the medicine, for example: a microwave, hot water, or direct sunlight. 
NE uporabljajte virov toplote za segrevanje zdravila, npr. mikrovalovne pečice, vroče vode ali neposredne sončne svetlobe.
Other side effects that have been reported 
Drugi neželeni učinki, o katerih so poročali
• 1 alcohol wipe 
• 1 alkoholni zloženec
There is a limited amount of data from the use of ixekizumab in pregnant women. 
Na voljo so le omejeni podatki o uporabi iksekizumaba pri nosečnicah.
Taltz that has been frozen must not be used. 
Zdravila Taltz, ki je zmrznilo, ne smete uporabiti.
Taltz is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group. 
Zdravilo Taltz ni priporočljivo za otroke in mladostnike, mlajše od 18 let, ker ga pri tej starostni skupini niso preučili.
Q. What if I cannot push in the plunger? 
V: Kaj če ne morem potisniti bata?
Treatment Week 
Tedni zdravljenja
Taltz can potentially cause serious side effects, including infections and allergic reactions. 
Zdravilo Taltz lahko morda povzroči resne neželene učinke, vključno z okužbami in alergijskimi reakcijami.
Air bubbles are not a problem in this type of injection. 
Zračni mehurčki pri tovrstnem injiciranju ne predstavljajo težav.
Influenzai, Rhinitis, Oral candidiasisd, Conjunctivitisi, Cellulitise 
Občasni gripai, rinitis, oralna kandidazad, konjunktivitisi, celulitise
- tinea (fungal) infections such as athlete's foot. 
- tinea (glivične) okužbe kože, kot je npr. atletsko stopalo,
This was related primarily to early delivery or maternal neglect of offspring, common findings in nonhuman primate studies, and considered clinically irrelevant. 
To je bilo povezano predvsem s prezgodnjo skotitvijo ali maternalnim zanemarjanjem mladičev, kar je v študijah na nehumanih primatih pogosto opaženo in se ne smatra za klinično pomembno.
The most frequent injection site reactions observed were erythema and pain. 
Najpogostejši reakciji na mestu injiciranja, ki so ju opazili, sta bili eritem in bolečina.
Cases of new or exacerbations of Crohn's disease and ulcerative colitis have been reported. 
Poročali so o novih primerih ali poslabšanjih Crohnove bolezni in ulceroznega kolitisa.
Taltz has been shown to lower (within 1 week of treatment) levels of C-reactive protein, which is a marker of inflammation. 
Dokazali so, da zdravilo Taltz znižuje (v prvem tednu zdravljenja) ravni C-reaktivnega proteina, ki je pokazatelj vnetja.
Ixekizumab does not bind to ligands IL-17B, IL-17C, IL-17D, IL-17E or IL-17F. 
Iksekizumab se ne veže na ligande IL-17B, IL-17C, IL-17D, IL-17E ali IL-17F.
This may be given by your doctor or nurse. 
To vam lahko da zdravnik ali medicinska sestra.
1d Wash your hands before you inject your medicine. 
1d Pred injiciranjem zdravila si umijte roke.
Clearance is independent of dose. 
Očistek ni odvisen od odmerka.
However, the data concerning immunisation were insufficient to conclude on an adequate immune response to these vaccines following administration of Taltz. 
Podatki v zvezi s cepljenjem pa niso bili zadostni, da bi na njihovi podlagi lahko sklepali, da je imunski odziv na ti cepivi po dajanju zdravila Taltz zadosten.
Serious hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Resna preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Injection sites may be alternated. 
Mesta injiciranja je mogoče spreminjati.
Q. What if I heard more than 2 clicks during my injection-2 loud clicks and a soft one. 
V: Kaj če med injiciranjem slišim več kot dva klika - dva glasnejša klika in enega tišjega.
Maintenance of Response at Week 60 
Vzdrževanje odziva v 60. tednu
In SPIRIT-P1and SPIRIT-P2, improvements were shown in all components of the ACR scores including patient assessment of pain. 
V študijah SPIRIT-P1in SPIRIT-P2 so se izboljšanja pokazala v vseh komponentah ocen ACR, vključno z bolnikovo oceno bolečine.
Pull the needle cap off and throw it away. 
Snemite pokrovček igle in ga zavrzite.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik
Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC13 
Farmakoterapevtska skupina: zdravila za zaviranje imunske odzivnosti, zaviralci interlevkinov, oznaka ATC: L04AC13
Caution should be exercised when prescribing Taltz to patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and patients should be monitored closely. 
Previdnost je potrebna pri predpisovanju zdravila Taltz bolnikom z vnetno črevesno boleznijo, vključno s Crohnovo boleznijo in ulceroznim kolitisom, bolnike pa je treba skrbno spremljati.
- if you are receiving any other treatment for psoriasis (such as immunosuppressant or phototherapy with ultraviolet light) or for psoriatic arthritis. 
- če jemljete katero koli drugo zdravilo za zdravljenje psoriaze (npr. imunosupresiv ali fototerapijo z ultravijolično svetlobo) ali za zdravljenje psoriatičnega artritisa.
It is not known whether ixekizumab is excreted in human milk or absorbed systemically after ingestion. 
Ni znano, ali se iksekizumab izloča v materino mleko pri človeku in ali se sistemsko absorbira po zaužitju.
Such signs are listed under “Serious side effects” in section 4. 
Takšni znaki so navedeni v poglavju 4, pod naslovom "Resni neželeni učinki".
Guide to the parts 
Vodič po delih
Taltz can be used alone or with another medicine named methotrexate. 
Zdravilo Taltz lahko uporabljate samostojno ali skupaj z drugim zdravilom, imenovanim metotreksat.
Patients in these studies had a diagnosis of psoriatic arthritis (Classification Criteria for Psoriatic Arthritis [CASPAR] criteria) for a median of 5.33 years. 
Bolniki v teh študijah so imeli diagnozo psoriatičnega artritisa (po razvrstitvenih merilih za psoriatični artritis CASPAR - Classification Criteria for Psoriatic Arthritis) mediano 5,33 let.
If such an infection develops, monitor carefully and discontinue Taltz if the patient is not responding to standard therapy or the infection becomes serious. 
Če se taka okužba razvije, jo je treba natančno spremljati in prekiniti zdravljenje z zdravilom Taltz, če se bolnik ne odziva na standardno zdravljenje ali če okužba postane resna.
Significance level only provided for endpoint that was pre-defined and multiplicity tested. 
Ravni značilnosti so podane samo za opazovani dogodek, ki je bil opredeljen vnaprej in testiran glede večkratnosti primerjav.
Patients had at least moderate plaque psoriasis (defined as sPGA score of ≥ 3 and being candidates for phototherapy and/or systemic therapy) for at least 6 months. 
Bolniki so imeli najmanj zmerno psoriazo s plaki (definirano kot oceno sPGA ≥ 3 in so bili kandidati za fototerapijo in/ali sistemsko zdravljenje) v obdobju najmanj 6 mesecev.
Q. Do I need to hold the injection button down until the injection is complete? 
V: Ali moram držati gumb za injiciranje, dokler injiciranje ni končano?
In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately. 
V primeru prevelikega odmerjanja je priporočljivo, da bolnika spremljate, da bi lahko ugotovili morebitne znake ali simptome neželenih učinkov ter takoj uvedli ustrezno simptomatsko zdravljenje.
It is important not to try to inject yourself until you have been trained by your doctor or nurse. 
Pomembno je, da si zdravila ne poskušate injicirati sami, dokler vas zdravnik ali medicinska sestra ne pouči o tem.
Ixekizumab modulates biological responses that are induced or regulated by IL-17A. 
Iksekizumab modulira biološke odzive, ki jih sproža ali regulira IL-17A.
Clean your skin with an alcohol wipe. 
Z alkoholnim zložencem obrišite kožo.
From population pharmacokinetic analyses, the mean total volume of distribution at steady state was 7.11 L. 
Glede na analize populacijske farmakokinetike je bil povprečni skupni porazdelitveni volumen v stanju dinamičnega ravnovesja 7,11 l.
Taltz is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Taltz is indicated. 
Zdravilo Taltz je namenjeno za uporabo pod vodstvom in nadzorom zdravnika, ki ima izkušnje z diagnozo in zdravljenjem bolezni, za katere je zdravilo Taltz indicirano.
Non-clinical data from cynomolgus monkeys revealed no special hazards for humans based on repeatdose toxicity studies, safety pharmacology evaluations, and reproductive and developmental toxicity studies. 
Neklinični podatki pri opicah vrste javanski makak (Cynomolgus) niso pokazali nobenega posebnega tveganja za človeka na podlagi študij toksičnosti s ponavljajočimi odmerki, ocen farmakološke varnosti in študij reproduktivne toksičnosti in toksičnosti za razvoj.